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A b s t r a c t
Background: Major vessel stenoses are currently successfully treated with stent implantation. Recently, new cobalt-chromium
stents (Andrastents XL and XXL, Andramed, Germany) have been introduced into clinical practice. This alloy combines high
biocompatibility with radial strength and flexibility.
Aim: To present our experience with the use of Andrastents XL and XXL for the dilatation of stenosed pulmonary arteries,
coarctation of the aorta (CoA), and a stenosed superior vena cava (SVC).
Methods: The study group included 24 patients treated with 26 Andrastents. In 7 patients aged 23.3 (range 18–27) years,
with the mean body weight of 64.7 (range 50–77) kg, prestenting of a calcified pulmonary homograft was performed using
9 Andrastents XL or XXL (length of 30, 39, or 48 mm) before the Melody valve implantation. In one patient with a long and stiff
stenosis, 3 stents were necessary. In 12 patients with native CoA aged 30.1 (range 9–55) years, with the mean body weight of
60 (range 25–105) kg, twelve Andrastents XL or XXL (length of 30, 39, or 48 mm) were implanted. In 4 patients with the right
or left pulmonary artery stenosis close to the bifurcation (age 8.5 [range 6–10] years, body weight 27.3 [range 17–33] kg),
4 Andrastents 30 XL were implanted. In one child (age 7.5 years, body weight 21.7 kg) with a iatrogenic SVC stenosis (after
2 venous cannulations necessary for 2 surgical corrections of his double-outlet right ventricle), the stenosed site was dilated
using Andrastent 21 XL.
Results: All procedures were performed successfully. No stent fractures were observed during the follow-up. The mean
pressure gradient was reduced from 42.4 to 18 mm Hg (RVOT) in patients who underwent Andrastent and Melody valve
implantation, from 54.1 to 13.2 mm Hg in patients with CoA, and from 49 to 21.7 mm Hg in patients with pulmonary artery
stenosis. No aneurysm formation, stent migration, or rupture of the treated vessel during stent implantation were observed in
any patient. The mean fluoroscopy time during stent implanatation was 6.6 min in CoA, 8.8 min in pulmonary artery stenosis,
24.8 min during implantation of Melody valve (with prestenting of RVOT with Andrastents) and 17.6 min during SVC dilation.
Procedural outcomes (evaluated using noninvasive methods) remained favourable during the follow-up (0.5–21 months), with
no complications observed.
Conclusions: Implantation of Andrastents XL or XXL is a very good therapeutic option in the treatment of major vessel
stenoses.
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INTRODUCTION
Stent implantation plays an increasing role in dilating steno-
sed vessels in congenital and structural cardiovascular defects.
A number of stent designs are currently available to use in the
treatment of major vessel stenoses. However, only few of them
have properties which allow their use in vessels with a dia-
meter above 20 mm. Such stents should be characterised by
flexibility (which allows their passage through curved vascu-
lar segments during implantation) and high radial strength al-
lowing avoidance of elastic recoil. Recently, new cobalt-chro-
mium stents (Andrastents XL and XXL, Andramed, Germany)
have been introduced into clinical practice that seem to com-
bine these characteristics. They were approved for the use in
the European Union (CE mark) in 2009.
In this report, we present our initial experience with the
use of these stents in dilating coarctation of the aorta, right
ventricular outflow tract (RVOT) (calcified homografts), pul-
monary arteries (PA), and the superior vena cava (SVC). To
the best of our knowledge, it is the first published report on
the use of Andrastents in clinical practice, although this issue
has been debated on several occasions during international
congresses [1–3].
METHODS
This descriptive clinical study has been approved by a local
ethics committee, and stent implantation procedures were
performed upon obtaining patient or caregiver consent. The
purpose of the study was to describe immediate efficacy of
Andrastent implantation, possible complications, and early
treatment outcomes. Stent implantation procedures were
performed between June 2009 and February 2011. Inclu-
sion criteria for the use of the stent in aortic, RVOT, and PA
stenoses included pressure gradient above 20 mm Hg (by di-
rect haemodynamic measurements) or, in case of PA and SVC
stenoses, a lower gradient associated with markedly abnor-
mal pulmonary flow distribution or resulting in symptoms of
systemic venous congestion.
In all patients, Andrastents XL or XXL were implanted.
Table 1 describes detailed patient characteristics, with patient
numbering reflecting the order of implantation procedures.
The mean patient age was 23.1 ± 12.9 years, and body weight
was 53.7 ± 21.9 kg.
In 12 patients (age range 9–47 years, mean age 30.1 years,
body weight 25–105 kg, mean 60 kg), intervention was per-
formed due to a native coarctation of the aorta located wi-
thin the aortic isthmus (Figs. 1A, B). A non-stenosed bileaflet
aortic valve was present in 7 of these patients. In the patient
# 5, ascending aortic and aortic arch hypoplasia was present
that had been previously dilated surgically.
In 7 patients (age range 18–27 years, mean age 23.3 years;
body weight 50–77 kg, mean 64.7 kg), prestenting of a calci-
fied pulmonary homograft was performed before the Melody
stented valve (Medtronic Inc.) implantation (Figs. 2A, B). In
4 patients, the homograft was implanted due to tetralogy of
Fallot/pulmonary atresia with ventricular septal defect (VSD)
(patients # 1, 4, 9, 15 in Table 1), in 2 patients due to trans-
position of the great arteries with VSD after a previous Rastelli
procedure (patients # 3, 19 in Table 1), and in one patient
due to critical pulmonic valvular stenosis (patient # 14).
In 4 patients (age range 6–10 years, mean age 8.5 years;
body weight 17–33 kg, mean 27.3 kg), Andrastents were used
to dilate the ostium of the right (RPA) or left pulmonary artery
(LPA) (Figs. 3A, B). The LPA was dilated in 3 patients (# 6, 13,
20) and the RPA in one patient (# 2). In the patient # 20, the
initial diagnosis was transposition of the great arteries, with
anatomical correction in the neonatal period, followed by
later (at the age of 2 year) surgical dilation of both PA using
a patch. During cardiac catheterisation, stenoses of lobar bran-
ches of the RPA were found and dilated using balloon angio-
plasty simultaneously to Andrastent implantation to the LPA.
Patients # 6 and # 13 underwent a surgical correction of
double outlet right ventricle (DORV). Patient # 2 underwent
common truncus arteriosus type II correction using a homo-
graft. In this patient, both PA ostia were stenosed, with An-
drastent implantation to the LPA and a 27 mm Genesis stent
(Cordis) implantation to the RPA.
In one child (age 7.5 years, body weight 21 kg) following
two previous surgical DORV corrections, with symptoms of
SVC syndrome (patient # 24 in Table 1), an Andrastent was
implanted into the stenosis site in the SVC (Figs. 4A, B).
Andrastents (Andramed GmbH, Reutlingen, Germany)
are constructed from a cobalt-chromium alloy. They have mul-
ticellular hybrid cell structure, constructed from 12 zig-zag
elements. This stent design combines open and closed cell
structures.
Procedures were performed in local anaesthesia in adults
and in general anaesthesia in children. A diagnostic cardiac
catheterisation was performed before the intervention in all
cases. Detailed measurements of the stenosed vessels and
pressure gradients before and after the procedures were made.
Femoral artery access was used for coarctation of the aorta,
and femoral vein access was used in the remaining cases. After
crossing the stenosis site and advancing a superstiff catheter
through the stenosis, a long Mullins sheath (Cook, Denmark)
of an appropriate diameter was introduced. Following cathe-
terisation, we did not use a hemostatic device to close the
punctured vessel in any of the patients. Stent implantation
was performed following precise angiographic delineation of
the stenosed site. Stents were manually mounted on a ballo-
on catheter. For implantation, it was necessary to use vascu-
lar sheaths that were 2 F larger compared to the size required
for the used balloon catheter. We used BIB (Numed), Power-
flex (Cordis), and Maxi LD (Cordis) balloons (for details see
Table 1). Andrastents are available in two sizes: XL, which
may be dilated to the diameter of 25 mm, and XXL, which
may be dilated to the diameter of 32 mm. Comparison of
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Table 1. Characteristics of the 24 patients treatment using 26 Andrastents XL and XXL
Patient Sex Age Weight Implantation Stent Balloon         Gradient [mm Hg] Follow-up
no. [years]  [kg]  site Before After [months]
1 M 20 77 PT 39XL BIB 10/20 54 25 21
2 M 6 17 RPA 30XL P-Flex 10 96 49 19
3 M 25 77 RVOT/PT 39XXL BIB 11/22 27 24 14
4 M 18 54 RVOT/PT 39XXL BIB 11/22 26 11 14
5 F 51 70 CoA 39XL MaxiLD 16 30  3 12
6 M 9 30 LPA 30XL MaxiLD14 23 10 12
7 F 19 47 CoA 39XXL MaxiLD 16 49 26 12
8 F 39 54 CoA 39XL MaxiLD 14 43 15 11
9 F 24 53 RVOT/PT 39XXL BIB 11/22 32  8 10
10 M 47 75 CoA 39XXL BIB 10/20 60  1 9
11 F 16 51 CoA 48XL MaxiLD 14 46 19 7
12 M 31 83 CoA 48XXL BIB 11/22 85 26 7
13 F 10 33 LPA 30XL MaxiLD 16  4  0 7
14 F 27 72 PT 30XXL BIB 11/22 48  21 6
15 F 22 50 RVOT/PT 2 × 39XXL BIB 11/22 58 14 6
1 × 49XXL
16 F 22 55 CoA 39XL BIB 18 31 0 6
17 F 15 41 CoA 39XL MaxiLD 15 59 0 5
18 M 41 105 CoA 30XL MaxiLD 14 66 26 5
19 M 27 70 RVOT/PT 39XXL BIB 10/20 52 23 4
20 M 9 29 LPA 30XL MaxiLD 15 73 28 2
21 M 41 54 CoA 39XL MaxiLD 16 37  7 1
22 M 9 25 CoA 30XL P-Flex 12 89 22 0.5
23 F 17 45 CoA 30XXL P-Flex 12 47 20 0.5
24 M 7.5 21 SVC 21XL P-Flex 12 9 1 0.5
Mean ± SD 23.1 ± 12.9 53.7 ± 21.9 47.7 ± 23.5 15.8 ± 12.2
M — male; F — female; RVOT — right ventricular outflow tract; PT — pulmonary trunk; CoA — coarctation of the aorta; LPA — left pulmonary artery;
RPA — right pulmonary artery; SVC — superior vena cava; BIB — balloon in balloon catheter; P-flex — Powerflex balloon catheter; MaxiLD — MaxiLD
balloon catheter
Figure 1. A 14-year-old male with congenital coarctation of the aorta. Aortography in a LAO 90 degree view; A. Before implanta-
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Figure 2. A 20-year-old man following surgical correction of tetralogy of Fallot, with a calcified homograft showing evidence of
both stenosis and regurgitation; A. Angiographic image (LAO 30 + SU 10 view) of the pulmonary artery following homograft
prestenting using an Andrastent 39 XL (contrast agent injected through the Multitrack catheter); B. Fluoroscopy (LAO 90 degrees
view). The same patient following implantation of a stented Melody valve into the previously implanted Andrastent (note the
difference between less radioopaque Andrastent structure compared to that of the CP stent, on which the Melody valve is mounted)
A B
Figure 3. A 9-year-old boy with a significant left pulmonary artery stenosis following surgical double outlet right ventricle correc-
tion. Pulmonary angiography (LAO 30 + SU 10 view); A. Before implantation; B. After implantation of an Andrastent 30 XL
A B
Figure 4. A 7.5-year-old boy with a iatrogenic stenosis of the superior vena cava (following two surgical double outlet right
ventricle corrections performed using cardiopulmonary bypass). Angiography of the superior vena cava in a PA view;
A. Before implantation; B. After implantation of an Andrastent 21 XL
A B
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selected technical characteristics of the stents used to dilate
major vessels is shown in Table 2. Both Andrastent sizes (XL
and XXL) are available with the length of 13, 17, 21, 26, 30,
39, 48, and 57 mm.
Following stent implantation procedure, all patients under-
went follow-up clinical evaluations (physical examination, ECG,
and echocardiography) initially every 3 months (during the first
year after the implantation) and semiannually thereafter. An ima-
ging study (angiography, MRI or CT angiography) was planned in
all patients at 2 years following the implantation.
RESULTS
We used 26 Andrastents in 24 patients. All procedures were
performed successfully. No stent migration, stent fracture, or
aneurysm development in the treated vessel were observed
in any patient. A significant dilatation of the stenosed site was
obtained in all cases. Mean pressure gradient (by direct measu-
rements) decreased from 47.7 ± 23.5 to 15.8 ± 12.2 mm Hg.
In one patient with a long, narrowed and calcified homograft
following the repair of tetralogy of Fallot, three Andrastents
(length 39, 39, and 49 mm) had to be successively implanted
(patient # 15 in Table 1).
In patients with coarctation of the aorta, pressure gra-
dient by direct invasive measurements before Andrastent
implantation ranged from 31 to 89 (mean 54.1) mm Hg, com-
pared with 3 to 26 (mean 13.2) mm Hg after the implanta-
tion. Total fluoroscopy time ranged from 4 to 13 (mean 6.6)
min. Elective stent redilatation was performed in two patients
at 9 and 12 months, respectively (patients # 7 and # 8).
In patients undergoing prestenting of the calcified ho-
mograft before the Melody valve implantation, pressure gra-
dient across the homograft ranged from 26 to 58 (mean
42.4)  mm Hg, compared to 8 to 25 (mean 18) mm Hg after
the implantation. Total fluoroscopy time including the Melo-
dy valve implantation ranged from 18 to 41 (mean 24.8) min.
In patients with PA stenosis, pressure gradient before the
implantation ranged from 4 to 96 (mean 49) mm Hg, compa-
red to 0 to 49 (mean 21.7) mm Hg after the implantation. To-
tal fluoroscopy time ranged from 8.7 to 36.7 (mean 8.8) min.
In the child with stenosed SVC, venous pressure gradient
decreased from 9 to 1 mm Hg, along with resolution of head
and face oedema. Total fluoroscopy time during this proce-
dure was 17.6 min.
Follow-up noninvasive evaluations showed a good ef-
fect of the procedure in all patients, with no increase in pres-
sure gradient. The patients remained in good clinical condi-
tion and no complications were observed. The duration of
follow-up ranged from 0.5 to 21 months.
DISCUSSION
Use of stents to dilate large vessels requires appropriate tech-
nical characteristics of these devices, primarily in regard to
radial strength and stability of the implanted stent. First such
stents that were widely introduced into clinical practice were
steel Palmaz stents [4] with a closed-cell design. Although
effective, they were associated with a number of disadvanta-
ges, including stiffness and sharp margins resulting in relative-
ly numerous complications that finally resulted in withdrawal
of these stents [5]. A new generation of these stents, named
Genesis, was characterised by similar radial strength as com-
pared to the Palmaz stents but these stents were much more
flexible [6]. Next, a stent with an open-cell design was intro-
duced, known as Intrastent. These stents were similar to the
Genesis stents in regard to radial strength and flexibility, but
also had an important advantage of no shortening during di-
latation, a significant flaw of other stents [7]. A major advan-
tage was the introduction of Cheatham Platinum (CP) stents,
initially designed for dilating coarctation of the aorta [8, 9].
These stents were constructed from a platinium-iridium al-
loy, had rounded margins and produced much less compli-
cations as compared to other stents [10]. They were also cha-
racterised by large radial strength and flexibility. Next innova-
tion was the introduction of covered stents which have a bare
metal framework similar to all stents described above but are
covered with an additional external layer. In covered CP stents
and Advanta V12 stent, this is a polytetrafluoroethylene lay-
er. A potential advantage of these stents is the protection af-
forded to the vessel wall in case of its rupture, and an ability
to exclude concomitant aneurysmal lesions. A disadvantage
is the risk of adjacent side branch closure in case of stent
migration. Generally, experience with the use of covered stents
is not large [11, 12].
Table 2. Comparison of technical characteristics of different stents
Stent Genesis XD Intrastent LD Andrastent XXL CP(8Z)
Length [mm] 38 35 48 45
BIB* (15 mm profile) [F] 10 10 10 11
Wire thickness [inches] 0.010 0.011 0.011 0.013
Length [mm] at 12 mm diameter 33.2 35 46.5 42.7
Radial strength at 2 mm compression 4.4 5.4 6.9 6.9
Max. diameter [mm] 18.5 26 32 28
*Sheath size required for the stent inserted using a balloon-in-balloon (BIB) catheter with the optimal diameter of 15 mm
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It is still debated which stent type, bare metal or covered,
is superior. This dilemma has not been solved with the recent
publication of the European Society of Cardiology guidelines
for the management of grown-up congenital heart disease pa-
tients [13]. Our own experience in the interventional treatment
of coarctation of the aorta includes more than 200 patients
[14]. Our present findings show high utility and efficacy of An-
drastents in dilating various vessel stenoses but also indicate
similar technical properties of these stents as compared to wi-
dely used CP stents (Table 2). It seems that the design of An-
drastents, combining open and closed cell structures, has the
respective advantages of both, i.e. flexibility and ability to adapt
to vessel curvatures are combined with high radial strength. In
case of prestenting calcified homografts before implantation of
a Melody stented valve, the use of Andrastents allows determi-
ning whether potential stent fracture involves the Melody va-
lve stent or not, as the latter is mounted on a CP stent.
Another important practical issue is a lower cost of An-
drastents as compared to CP stents [15].
CONCLUSIONS
Implantation of Andrastents is a very attractive and effective
therapeutic option in the treatment of major vessel stenoses.
However, further data regarding long-term outcomes of this
treatment are necessary.
Conflict of interest: none declared
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Przezskórne poszerzanie koarktacji aorty,
zwężonych tętnic płucnych (lub homograftów)
i żyły głównej górnej za pomocą
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S t r e s z c z e n i e
Wstęp: Zwężenia dużych naczyń aktualnie skutecznie leczy się za pomocą implantacji stentów. Ostatnio do praktyki klinicz-
nej wprowadzono nowe stenty kobaltowo-chromowe (Andrastent XL i XXL). Powyższy stop zapewnia wysoką biokompaty-
bilność oraz połączenie wysokiej siły odśrodkowej stentu z jego giętkością.
Cel: Celem pracy było przedstawienie własnych doświadczeń w zastosowaniu Andrastentów XL i XXL w poszerzaniu koarkatcji
aorty (CoA), zwężeń gałęzi tętnicy płucnej (TP), zwapniałych homograftów w pozycji płucnej i żyły głównej górnej (SVC).
Metody: Leczeniem objęto 24 pacjentów, u których wszczepiono 26 Andrastentów. U 7 z nich w wieku 23,3 roku (18–27 lat),
o masie ciała 64,7 (50–77) kg przed implantacją zastawki płucnej na stencie Melody dokonano prestentowania zwapniałego
homgraftu za pomocą 9 Andrastentów XL lub XXL o długości 30, 39 lub 48 mm. U 1 pacjenta z długim niepodatnym
zwężeniem wszczepiono 3 stenty. U kolejnych 12 osób w wieku 30,1 roku (9–55 lat), o masie ciała 60 (25–105) kg
z wrodzoną CoA dokonano implantacji Andrastentów XL lub XXL o długości 30, 39 lub 48 mm. U kolejnych 4 pacjentów
w wieku 8,5 roku (6–10 lat) i o masie ciała 27,3 (17–33) kg zastosowano stenty XL 30 do prawej bądź lewej gałęzi płucnej
blisko jej odejścia od pnia płucnego. U 1 dziecka w wieku 7,5 roku, o masie ciała 21 kg zwężoną jatrogennie SVC (po dwóch
kaniulacjach związanych z operacją przeprowadzoną w krążeniu pozaustrojowym) poszerzono tę zmianę za pomocą An-
drastentu XL 21.
Wyniki: Wszystkie zabiegi ukończono pomyślnie, uzyskując spadek gradientu ciśnień w przypadku CoA z 54,1 do 13,2 mm Hg;
poszerzania RVOT (homograftu) z 42,4 do 18 mm Hg, gałęzi TP z 49 do 21,7 mm Hg i zwężenia SVC z 9 do 1 mm Hg.
Podczas implantacji nie stwierdzono ani jednego przypadku migracji stentu, jego pęknięcia czy powstania tętniaka. Średni
czas fluoroskopii wynosił w przypadku: implantacji Andrastentu do CoA — 6,6 min; implantacji zastawki Melody (z presten-
towaniem Andrastentem RVOT) — 24,8 min, poszerzania gałęzi TP — 8,8 min i poszerzania SVC — 17,6 min. W dalszej
obserwacji (od 0,5 do 21 miesięcy) stan pacjentów pozostawał dobry, w badaniach nieinwazyjnych utrzymywał się dobry
wynik zabiegu i nie zanotowano powikłań.
Wnioski: Przezskórne poszerzanie zwężonych dużych naczyń za pomocą Andrastentów stanowi bardzo dobrą opcję tera-
peutyczną.
Słowa kluczowe: wrodzone wady serca, przezskórna implantacja stentów
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